The 2nd edition of Asebio Investor Day attracted around 300 participants and 60 international investors Blog Post

26 September saw the 2nd edition of the Asebio Investor Day, which was organised by Asebio with the collaboration of Barcelona Science Park (PCB), the Biotechnology Markets Platform) ICEX Spain Trade and Investment and the Alternative Spanish Equity Market. Droplite, Molomics, Ona Therapeutics and SOM Biotech, all based at PCB, were among 50 companies selected to present their projects at the financing forum, in which 57 investors from 10 countries around the world participated.

 

Researchers from IBEC and IRB Barcelona awarded by “la Caixa” for their pioneering research projects Blog Post

On 16 September, ”la Caixa” Banking Foundation presented the 79 grants for national and international research and innovation projects of excellence. Among the beneficiaries of funding from ”la Caixa” are researchers Eduard Batlle, Raúl Méndez, Meritxell Teixidó and Enrique Marcos, from the Institute for Research in Biomedicine (IRB Barcelona), and José Antonio del Río, Pau Gorostiza and Samuel Sánchez, from the Institute for Bioengineering of Catalonia (IBEC).

 

Biomarkers in blood for faster diagnosis: a new GAEM Accelerator project Blog Post

The GAEM Foundation, headquartered in Barcelona Science Park (PCB) and engaged in promoting biomedical research to cure multiple sclerosis, has added a study conducted by Institut d’Investigació Biomèdica de Girona (IDIBGI) to its Project Accelerator Programme. The objective of the study, led by Dr Jordi Tomàs Roig, is to discover new markers that enable us to predict a patient’s evolution from a simple blood test, while contributing to the design of epigenetic drugs to slow down the disease’s progression.

 

Nanovectors could improve the combined administration of antimalarial drugs Blog Post

Encapsulating two drugs with different properties into nanovesicles surrounded by antibodies can greatly improve their delivery and efficacy, according to a study led by Xavier Fernández Busquets, director of the joint Nanomalaria unit at the Institute for Bionengineering of Catalonia (IBEC), in the Barcelona Science Park, and the Barcelona Institute for Global Health (ISGlobal), supported by ”la Caixa”.

 

Researchers decipher the structure and mechanism of action of a key complex involved in bacteriophage T7 infection Blog Post

Scientists from the Institute for Research in Biomedicine (IRB Barcelona), at the Barcelona Science Park, and the Spanish National Research Council (CSIC) have combined cryomicroscopy and crystallography techniques to study the bacteriophage T7. The study, published in Nature Communications, reveals the opening and closing mechanism of the portal protein during the maturation of the viral capsid, the structure that carries the genetic material of the virus. Deciphering how work the Bacteriophages –viruses that infect bacteria– helps us to understand how others pathogenic affect us and, at the same time, they are a new focus of attention for researchers given their potential as an alternative to antibiotics.

 

 

p38 protein regulates the formation of new blood vessels in tumours Blog Post

Researchers from the Institute for Research in Biomedicine (IRB Barcelona) at the Barcelona Science Park publish a study in the journal Nature Communications addressing the role of the p38 protein in angiogenesis—the formation of new blood vessels—a critical process that fuels tumour cells and allows them to grow and eventually develop metastases.

 

A research team develops a mini-factory of human cardiac tissue Blog Post

Researchers from the Institute for Bioengineering of Catalonia (IBEC) at the Barcelona Science Park, in collaboration with scientists from the Centre of Regenerative Medicine in Barcelona (CMR[B]), the University of Barcelona (UB), the Polytechnic University of Catalonia (UPC) and the CIBER-BBN have developed a system which is capable of producing tissues in a laboratory that simulate the behaviour of the human heart. The new platform, named CardioSlice, could be used to pre-evaluate the toxicity of drugs in the heart without using animal models. The results of this innovation work have announced in an article recently published in the journal Stem Cell Reports.

 

CataloniaBioHT participates in the Annual Advisory Committee of the Catalonia’s Cluster Programme Blog Post

Last Thursday, the president of CataloniaBio & HealthTech (CataloniaBioHT), Jaume Amat, participated in the Annual Advisory Committee of the Catalonia’s Cluster Programme, promoted by ACCIÓ, alongside the other presidents of the 30 accredited clusters. The association, founded in 2017 as a result of the merger of CataloniaBio and HeathTech Cluster and headquartered in the Barcelona Science Park, has over 160 companies and agents in the field of biomedicine and health. 

 

The GAEM ‘Value Company’ Certification is launched Blog Post

GAEM Foundation, based in the Parc Científic de Barcelona Science Park, has launched the GAEM ‘Value Company’ Certification, recognising the most avant-garde companies committed to Corporate Social Responsibility (CSR) and social well-being. With this seal, the foundation aims to continue promoting biomedical research to cure multiple sclerosis and contribute to raising awareness of the importance of innovation and science in our society.